What is the recommended treatment regimen for hyperthyroidism, including first-line antithyroid drugs, beta‑blocker use, duration of therapy, and definitive treatment options?

Hyperthyroidism Treatment

First-Line Antithyroid Drug Therapy

Methimazole (MMI) should be used as the first-line antithyroid drug in virtually all patients choosing medical therapy for Graves' disease, with the critical exception of the first trimester of pregnancy when propylthiouracil (PTU) is mandatory. 1

Initial Dosing and Titration

• Start MMI at 10-20 mg daily as a single dose to restore euthyroidism
• Once euthyroid, reduce to maintenance dose of 5-10 mg daily 1
• PTU dosing (when required): Start 50-150 mg three times daily, reduce to 50 mg 2-3 times daily for maintenance 1

Critical Safety Monitoring

Before initiating ATD therapy, obtain:

• Complete blood count with differential
• Liver function tests (bilirubin and transaminases) 1

Patients must be instructed to immediately stop medication and contact their physician if they develop:

• Fever, pharyngitis (agranulocytosis warning)
• Jaundice, dark urine, acolic stools, abdominal pain, nausea, fatigue (hepatotoxicity warning)
• Pruritic rash, arthralgias 1

Beta-Blocker Use

Beta-adrenergic blockade should be given to:

1. All elderly patients with symptomatic thyrotoxicosis (mandatory)
2. Any patient with resting heart rate >90 bpm (mandatory)
3. Any patient with coexistent cardiovascular disease (mandatory)
4. All other patients with symptomatic thyrotoxicosis (strongly consider) 1

Beta-blockers provide symptomatic relief of tachycardia, anxiety, and tremor within 4-8 weeks while awaiting ATD effect 1.

Duration of Therapy

Standard ATD course: 12-18 months 2, 3

However, the evidence shows significant nuance:

• Approximately 50% of patients relapse after a standard 12-18 month course 4, 5
• Long-term ATD treatment (5-10 years) reduces recurrence to only 15% compared to 50% with short-term treatment 4

Predictors of Relapse (indicating need for definitive therapy):

• Age <40 years
• Free T4 ≥40 pmol/L at diagnosis
• TSH-receptor antibodies >6 U/L
• Goiter size ≥WHO grade 2
• Persistently elevated TSH-receptor antibodies at 12-18 months 4, 3

If TSH-receptor antibodies remain elevated at 12-18 months, either continue MMI for another 12 months or proceed to definitive therapy 1, 3.

Definitive Treatment Options

When ATD therapy fails or relapse occurs, three definitive options exist:

1. Radioactive Iodine (RAI) - 131I Therapy

Administer sufficient 131I in a single dose (typically 10-15 mCi) to render the patient hypothyroid 1, 6. This is the goal—not euthyroidism, but hypothyroidism for definitive cure.

Pre-treatment Preparation:

• Stop MMI 3-7 days before and after RAI to avoid reducing efficacy 2, 6
• Beta-blockers are mandatory in elderly, symptomatic patients, or those with free T4 2-3 times upper limit of normal 1, 2
• Consider pre-treatment with MMI in fragile patients (elderly, cardiovascular disease, severe hyperthyroidism), then stop 3-7 days before RAI 2

Absolute Contraindications:

• Pregnancy or planned pregnancy within 4-6 months
• Breastfeeding
• Inability to follow radioprotection rules 2

Special Consideration - Graves' Ophthalmopathy:

• Mild active ophthalmopathy: Consider concurrent corticosteroids 1
• Moderate-to-severe or sight-threatening ophthalmopathy: RAI is contraindicated; use MMI or surgery instead 1
• Smokers with ophthalmopathy choosing RAI: Concurrent corticosteroids are mandatory 1

Follow-up:

• Assess free T4 and total T3 at 1-2 months post-RAI
• If still thyrotoxic, monitor every 4-6 weeks
• Retreatment indicated if hyperthyroidism persists at 6 months or minimal response at 3 months 1

2. Thyroidectomy

Total or near-total thyroidectomy should be performed (not subtotal) 1

Pre-operative Preparation:

• Render euthyroid with MMI
• Add potassium iodide in the immediate preoperative period 1

Critical Requirement:

Surgery must be performed by a high-volume thyroid surgeon to minimize complications (hypoparathyroidism and recurrent laryngeal nerve paralysis occur in 1-5% with experienced surgeons) 1, 7

Indications Favoring Surgery:

• Large goiter
• Coexisting suspicious thyroid nodules
• Moderate-to-severe ophthalmopathy (when RAI contraindicated)
• Patient preference for rapid definitive control without radiation
• Pregnancy (if necessary, perform during second trimester) 1, 2

Special Population: Pregnancy

This requires a completely different algorithm:

First Trimester:

• PTU is mandatory (MMI causes rare but serious birth defects: aplasia cutis, choanal/esophageal atresia) 1
• Women on MMI planning pregnancy: Switch to PTU immediately upon positive pregnancy test 1

Second and Third Trimesters:

• Switch from PTU to MMI at beginning of second trimester (PTU carries risk of potentially fatal hepatotoxicity) 1

Treatment Goal:

• Use lowest ATD dose to keep maternal free T4 at or slightly above upper limit of normal range
• Keep TSH suppressed
• Monitor monthly and adjust dose 1

Important Caveat:

• Transient hCG-mediated TSH suppression in early pregnancy should NOT be treated with ATDs 1

Common Pitfalls to Avoid

1. Do not use "block and replace" therapy (high-dose ATD plus levothyroxine)—this increases side effects without improving outcomes 1

2. Do not continue MMI through pregnancy—the teratogenic risk in first trimester is well-documented 1

3. Do not aim for euthyroidism with RAI—the goal is hypothyroidism to ensure cure 1

4. Do not perform thyroidectomy without high-volume surgeon—complication rates are significantly higher with inexperienced surgeons 1

5. Do not give RAI to patients with active moderate-to-severe ophthalmopathy—it will worsen eye disease 1

6. Do not delay switching from PTU to MMI in second trimester—PTU hepatotoxicity risk increases with duration of exposure 1